2503 ORAL Erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): results from a randomized phase II trial (EORTC 26034)

Martin J. van den Bent, T. Gorlia, R. Rampling et al.|European Journal of Cancer Supplements|2007

Cited by 5